37 results about "Tumor Antibodies" patented technology

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.

The invention relates to the field of biological medicine technology. Traditional anti-tumor antibodies are partly effective for target-positive patients. Chemotherapy drugs with high toxicity can kill tumor cells in a low concentration, but lack targeting. The invention provides a preparation method for an antibody drug conjugate that is anti-CD20-acceptors and inhibits tumor growth, and applications of the antibody drug conjugate in treating B lymphocyte malignant hyperplasia cancer.

The invention discloses a tumor-targeted CD38-pH low insertion peptide (pHLIP) fusion peptide. The fusion peptide is formed by connecting a pHLIP and a functional structure domain of CD38. The tumor microenvironment is acidic, under the acidic environment, the pHLIP can be inserted into a tumor cell membrane, by utilizing the properties of the pHLIP, the CD38 connected with the pHLIP is positionedon the surface of the tumor cell membrane in a targeted mode, through the technology, original tumor cells with tumor cell surfaces not expressing the CD38 can also be marked by the CD38, and thus antibody drugs aiming at the CD38 can exert the effects on the original tumor cells not expressing the CD38 as well. Through the research results, the indications of a specific tumor antibody drug are expanded, and clinical application prospects are good.

In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and / or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors.

The invention relates to a TM4SF3 protein used for preparing an anti-tumor antibody, and an application thereof, in particular to a TM4SF3 protein used for preparing an anti-tumor antibody, and an encoded nucleotide sequence thereof; the invention also relates to an antibody of the anti-TM4SF3 protein, and a preparation method and an application of the antibody in producing various biological preparations for curing various relative tumors; in addition, the invention also relates to a medicine composition including the antibody, and an application for inhibiting the tumor in the body, so thatthe effect of curing the tumor is achieved.

The invention relates to an antibody chip kit for diagnosis of various tumors. The kit includes an antibody chip, a tumor marker standard substance mixture, a biotin-labeled tumor marker detection antibody mixture, and a fluorescein Cy3-labeled streptavidin, wherein the antibody chip includes a substrate, 16 kinds of tumor marker specific antibodies fixed on the surface of the substrate, and two kinds of positive controls, and the tumor marker standard substance mixture is a freeze-dried mixture obtained by mixing 16 kinds of standard tumor marker standard substances together according to a certain amount. The kit can detect 16 clinical commonly used tumor markers, overcomes the defects of complicated operation, single detection index, low sensitivity and the like in the prior art, has the advantages of being cheap, convenient, sensitive, accurate, high in throughput, and less in amount of samples, and can be popularized and large-scaled in common laboratories.

The invention relates to a composite tumor antibody vaccine using bacterial nano magnetosomes as a carrier and a preparation method thereof. A composite tumor antibody vaccine is established by using bacterial nano magnetosomes as a carrier, and a new, simple and efficient antibody treatment method is established, which is a biological Therapy offers a new approach to immunity.

The invention discloses a compound antibody containing interferon alpha / tumor antibody / oxidized graphene as well as a preparation method and applications. The compound antibody contains interferon alpha, the tumor antibody and oxidized graphene, wherein the interferon alpha, the tumor antibody and oxidized graphene are connected through non covalent bonds, and the tumor antibody is rituximab or trastuzumab. The compound antibody containing interferon alpha / tumor antibody / oxidized graphene can effectively and directly kill most tumor cells and damage the microenvironment protecting the tumor cells, and meanwhile, the interferon alpha stimulates an immune system, breaks the tumor tolerance, and promotes the specific cellular activation of tumors or the release of cell factors, so that the purposes of shrinking or eliminating tumors, preventing relapse and finally completely treating tumors are achieved.

The invention relates to a multi-signal chimeric antigen receptor and its expression gene, its modified NK cell and its application. The chimeric antigen receptor includes a first fragment, a second fragment, and a self-cleaving polypeptide T2A connecting the first fragment and the second fragment. The first fragment includes a first signal peptide, a TCRγ chain and a TCRδ chain sequentially connected, and the second fragment Including the second signal peptide SP, tumor antibody, CD8 domain, 41BB intracellular domain and DAP12-ITAM domain connected in sequence, the C-terminus of the self-cleaving polypeptide T2A is connected to the TCRδ chain, and the N-terminus of the self-cleaving polypeptide T2A is connected to the first The two signal peptides SP are connected. Experimental results show that the above-mentioned multi-signal chimeric antigen receptor can be stably expressed in NK cells, can more quickly and specifically recognize and kill malignant tumor cells, and reduce the toxic and side effects of treatment.

The present invention is applicable to the field of biological gene technology, and provides a nanobody and its encoding gene, expression vector, host cell and application. The nanobody is a nanobody directed against the Siglec-15 extracellular specific region, which comprises at least one amino acid Nanobodies whose sequences are shown in SEQ ID NO.8, SEQ ID NO.13, SEQ ID NO.18, and SEQ ID NO.23. In the present invention, a nanobody capable of specifically binding to the extracellular region of Siglec-15 is obtained, which has great potential in the research and development of Siglec-15 therapeutic antibody, preferably an anti-tumor antibody treatment. The nanobody has strong and fast tissue penetration ability, and can enter dense solid tumor tissue to play a role; its molecular structure is relatively simple, and can be fermented and produced by Escherichia coli or yeast expression system, which greatly reduces the production cost.